MedTrace Logo

Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis

NCT01252420 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2010-12-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether a limited duration of treatment (two weeks of low molecular weight treatment) is a safe and effective treatment for distal deep vein thrombosis of the lower limb.

Conditions

Interventions

DRUG

Enoxaparin

1.5mg/kg daily for 2 weeks

Sponsors & Collaborators

  • Southern Health, Victoria

    collaborator UNKNOWN

  • Eastern Health, Victoria

    collaborator UNKNOWN

  • Royal Adelaide Hospital, Adelaide

    collaborator UNKNOWN

  • Prince of Wales Hospital, Sydney

    collaborator OTHER_GOV

  • Christchurch Hospital, NZ

    collaborator UNKNOWN

  • Auckland City Hospital

    collaborator OTHER_GOV

  • North Shore Hospital, New Zealand

    collaborator OTHER

  • Middlemore Hospital, New Zealand

    collaborator OTHER

  • Monash Medical Centre

    lead OTHER

Principal Investigators

  • Huyen Tran, MBBs(Hons), MClin Epidem · Monash Medical Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-11-30
Completion
2014-11-30

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01252420 on ClinicalTrials.gov